ஜப்பானிய சமூகம் க்கு தடுப்பூசி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Flu vaccines in Japan delayed by supply shortages amid pandemic
japantimes.co.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantimes.co.jp Daily Mail and Mail on Sunday newspapers.
Japan faces influenza vaccines supply shortage amid COVID-19 pandemic - World News
sina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com Daily Mail and Mail on Sunday newspapers.
E-Mail
A new study looking across a large body of research finds further evidence for the safety of vaccines that are Food and Drug Administration-approved and routinely recommended for children, adults and pregnant women. The study updates a vaccine safety review that was released by the federal Agency for Healthcare Research and Quality in 2014. This in-depth analysis found no evidence of increased risk of serious adverse events following vaccines, apart from a few - previously known - associations, said Susanne Hempel, director of the Southern California Evidence Review Center.
The meta-analysis, published in the journal
Vaccine, does not address the safety of COVID-19 vaccines, but summarizes the results of 338 studies of other vaccines commonly given across the lifespan.
Credit: © Center for Integration of Science and Industry at Bentley University
The unprecedented development of COVID-19 vaccines less than a year after discovery of this virus was enabled by more than $17 billion of research on vaccine technologies funded by the NIH prior to the pandemic, according to new research from Bentley University sCenter for Integration of Science and Industry. The article, titled NIH funding for vaccine readiness before the COVID-19 pandemic, demonstrates the critical role this broad foundation of government-funded research plays in ensuring vaccine readiness.
The report, published today in the journal
Vaccine, examined the maturation of research and NIH funding for ten technologies that were applied in candidate COVID-19 vaccines as of July 2020. The maturation of these technologies was described in 51,530 published research papers from 2000-2019, of which 8,420 (16%) acknowledge NIH funding totaling $17.2 billion. Some of these technologies have be
news
Editorial: Japan vaccine rollout should prioritize safety, address fears The Mainichi © The Mainichi
Screening of new coronavirus vaccines has begun in Japan, with American firm Pfizer Inc. applying to the Ministry of Health, Labor and Welfare for special approval of the vaccine it developed.
A number of countries have already green-lit use of Pfizer s vaccine, and vaccinations have started in the U.S., U.K. and elsewhere. But the normal procedures have been truncated, leaving open the possibility of unexpected side effects. Tests in this country should go ahead with safety as their highest priority.
Vaccinations produce antibodies in inoculated people to fight pathogens and prevent infection or reduce the severity of symptoms.
vimarsana © 2020. All Rights Reserved.